Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 9/20 | 0.69 |
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812756 | 0.89 | DDX3X (0.80) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL1275926 | 0.87 | RAB9A (0.75) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL3460449 | 0.86 | DDX3X (0.70) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL17079606 | 0.86 | RAB9A (0.66) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL17084259 | 0.86 | RAB9A (0.67) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL687547 | 0.86 | RAB9A (0.66) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL13070081 | 0.86 | RAB9A (0.75) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL6799221 | 0.85 | RAB9A (0.73) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL27568751 | 0.84 | DDX3X (0.73) | DDX3XRAB9ANPC1MAPTKMT2A | |
| SCHEMBL17079620 | 0.83 | RAB9A (0.68) | DDX3XRAB9ANPC1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| US-9321766-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160096832-A1 | KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001051487-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1091943-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | Pfizer Products Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000477-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | DDX3X 3590/4885RAB9A 1779/4885NPC1 2649/4885 |
| US-20160096832-A1 | KINASE INHIBITORS | ABL1, LCK, ERBB2 | DDX3X 2023/4885RAB9A 2799/4885NPC1 4204/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | DDX3X 3590/4885RAB9A 1779/4885NPC1 2649/4885 |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | DDX3X, DDX1, DDX5 | DDX3X 1/4885RAB9A 873/4885NPC1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.